Drug intelligence / Profile preview

Shanjinlian

Development stage: Phase 2
Lead developer: Shanxi Yellow River Traditional Chinese Medicine
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Oral

Overview

Shanjinlian is a Traditional Chinese Medicine (TCM) formulation developed by Shanxi Yellow River Traditional Chinese Medicine Co., Ltd. for the treatment of the common cold, specifically targeting the Wind-Heat Syndrome (风热证). Formulated as a soft capsule, it is designed to clear heat and detoxify, which are standard therapeutic goals in TCM for viral respiratory infections. The drug has undergone clinical evaluation in China, including dose-finding studies and Phase 3 trials (e.g., CTR20241345) intended to support its registration and production for the relief of cold symptoms.

Brand names: Shanjinlian
Other names: Shanjinlian soft capsule山金连软胶囊

Beyond the preview

Go deeper on Shanjinlian.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanjinlian.